The Kallikrein-Kinin System

被引:0
作者
Tang, Sydney C. W. [1 ]
Leung, Joseph C. K. [1 ]
Lai, Kar Neng [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
来源
DIABETES AND THE KIDNEY | 2011年 / 170卷
关键词
CONVERTING ENZYME-INHIBITION; DIABETIC-NEPHROPATHY; TISSUE KALLIKREIN; RENAL KALLIKREIN; MESANGIAL CELLS; BRADYKININ; RECEPTOR; MICE; KIDNEY; ACTIVATION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Emerging evidence suggests a role of the kallikrein-kinin system (KKS) in the pathogenesis of diabetic nephropathy (DN). Tissue kallikrein 1 is a member of the tissue kallikrein family that is mainly responsible for the generation of kinins, and bradykinin (BK) is the principal kinin responsible for the biologic actions of the KKS that acts through the ubiquitous BK 2 receptor (B2R) and the inducible B1R. In the kidney, all KKS components are expressed. In particular, kallikrein 1 that is traditionally thought to be solely confined to the distal nephron has recently been identified in the proximal tubule of the human diabetic kidney. Current evidence suggests conflicting roles of the KKS in DN. For a renoprotective role of the KKS, BK reduces mesangial cell proliferation under the diabetic milieu; Akita B2R-/- or STZ-induced KLK-/- mice (T1DM) have more severe albuminuria and glomerulosclerosis, while antagonizing the B2R with icatibant attenuates the antiproteinuric effect of ramipril in db/db mice (T2DM). For a detrimental role of the KKS, BK upregulates tubular cell IL-6, CCL-2, and TGF-beta expression via ERK1/2 activation; the B2R-/- status protects against the development of DN lesions in STZ-injected mice, while blocking B2R with icatibant alleviates biochemical and histologic injuries in uninephrectomized db/db mice, These opposite findings may arise from multiple factors and call for further evaluation to clarify the role of the KKS in DN and diabetic tubulopathy. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:145 / 155
页数:11
相关论文
共 30 条
[1]   Inhibition of IGF-I-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin [J].
Alric, C ;
Pecher, C ;
Cellier, E ;
Schanstra, JP ;
Poirier, B ;
Chevalier, J ;
Bascands, JL ;
Girolami, JP .
KIDNEY INTERNATIONAL, 2002, 62 (02) :412-421
[2]   Kallikrein protects against microalbuminuria in experimental type I diabetes [J].
Bodin, Sophie ;
Chollet, Catherine ;
Goncalves-Mendes, Nicolas ;
Gardes, Joelle ;
Pean, Franck ;
Heudes, Didier ;
Bruneval, Patrick ;
Marre, Michel ;
Alhenc-Gelas, Francois ;
Bouby, Nadine .
KIDNEY INTERNATIONAL, 2009, 76 (04) :395-403
[3]  
Breyer MD, 2005, J AM SOC NEPHROL, V16, P27, DOI [10.1681/ASN.2009070721, 10.1681/ASN.2004080648]
[4]   Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model [J].
Buleon, Marie ;
Allard, Julien ;
Jaafar, Acil ;
Praddaude, Francoise ;
Dickson, Zara ;
Ranera, Marie-Therese ;
Pecher, Christiane ;
Girolami, Jean-Pierre ;
Tack, Ivan .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2008, 294 (05) :F1249-F1256
[5]   CELLULAR-LOCALIZATION OF TISSUE KALLIKREIN AND KALLISTATIN MESSENGER-RNAS IN HUMAN KIDNEY [J].
CHEN, LM ;
SONG, Q ;
CHAO, L ;
CHAO, J .
KIDNEY INTERNATIONAL, 1995, 48 (03) :690-697
[6]   Reflections on the tissue kallikrein and kallikrein-related peptidase family - from mice to men - what have we learnt in the last two decades? [J].
Clements, Judith A. .
BIOLOGICAL CHEMISTRY, 2008, 389 (12) :1447-1454
[7]   Bradykinin and des-Arg9-bradykinin metabolic pathways and kinetics of activation of human plasma [J].
Cyr, M ;
Lepage, Y ;
Blais, C ;
Gervais, N ;
Cugno, M ;
Rouleau, JL ;
Adam, A .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 281 (01) :H275-H283
[8]   Vasoactive potential of the B1 bradykinin receptor in normotension and hypertension [J].
Duka, I ;
Kintsurashvili, E ;
Gavras, I ;
Johns, C ;
Bresnahan, M ;
Gavras, H .
CIRCULATION RESEARCH, 2001, 88 (03) :275-281
[9]   Role of the B2 receptor of bradykinin in insulin sensitivity [J].
Duka, I ;
Shenouda, S ;
Johns, C ;
Kintsurashvili, E ;
Gavras, I ;
Gavras, H .
HYPERTENSION, 2001, 38 (06) :1355-1360
[10]  
GOLDSTEIN RH, 1984, J BIOL CHEM, V259, P9263